Berliner Boersenzeitung - Once-taboo ketamine booms for US at-home mental care

EUR -
AED 4.322512
AFN 81.008431
ALL 97.610159
AMD 449.741076
ANG 2.106185
AOA 1079.159835
ARS 1481.251332
AUD 1.778449
AWG 2.12125
AZN 2.003676
BAM 1.956004
BBD 2.367977
BDT 142.954879
BGN 1.954562
BHD 0.44362
BIF 3495.323193
BMD 1.176837
BND 1.498369
BOB 8.103878
BRL 6.492024
BSD 1.172722
BTN 101.327116
BWP 15.651629
BYN 3.838111
BYR 23066.014699
BZD 2.355775
CAD 1.600893
CDF 3396.35309
CHF 0.932803
CLF 0.028445
CLP 1115.888998
CNY 8.426868
CNH 8.413905
COP 4754.423438
CRC 592.461663
CUC 1.176837
CUP 31.186193
CVE 110.275072
CZK 24.585343
DJF 208.621713
DKK 7.463645
DOP 70.987388
DZD 152.555099
EGP 57.771804
ERN 17.652562
ETB 160.238378
FJD 2.628111
FKP 0.870508
GBP 0.867253
GEL 3.189247
GGP 0.870508
GHS 12.255119
GIP 0.870508
GMD 84.732712
GNF 10175.059015
GTQ 9.000899
GYD 245.223439
HKD 9.237621
HNL 30.708196
HRK 7.532461
HTG 153.884709
HUF 398.525381
IDR 19160.091087
ILS 3.920552
IMP 0.870508
INR 101.5862
IQD 1536.259893
IRR 49559.564856
ISK 142.209258
JEP 0.870508
JMD 188.119579
JOD 0.834323
JPY 171.969496
KES 151.462488
KGS 102.823942
KHR 4700.449279
KMF 494.85638
KPW 1059.21497
KRW 1609.28981
KWD 0.358947
KYD 0.977293
KZT 631.140326
LAK 25280.631195
LBP 105081.740809
LKR 353.806824
LRD 235.133474
LSL 20.593843
LTL 3.474895
LVL 0.711857
LYD 6.34166
MAD 10.546843
MDL 19.831064
MGA 5180.539188
MKD 61.566669
MMK 2470.300458
MNT 4220.581008
MOP 9.481487
MRU 46.545844
MUR 53.240152
MVR 18.118785
MWK 2033.511647
MXN 21.828101
MYR 4.963309
MZN 75.27023
NAD 20.593668
NGN 1794.147061
NIO 43.154491
NOK 11.895829
NPR 162.123874
NZD 1.944394
OMR 0.452496
PAB 1.172727
PEN 4.180135
PGK 4.929513
PHP 66.643719
PKR 333.873949
PLN 4.25242
PYG 8784.399462
QAR 4.27529
RON 5.072876
RSD 117.135316
RUB 92.264883
RWF 1695.176433
SAR 4.414972
SBD 9.750211
SCR 17.021093
SDG 706.681753
SEK 11.192713
SGD 1.501368
SHP 0.924809
SLE 27.008153
SLL 24677.698279
SOS 670.169751
SRD 42.892196
STD 24358.159906
STN 24.50255
SVC 10.261068
SYP 15301.194295
SZL 20.584142
THB 37.932992
TJS 11.252223
TMT 4.1307
TND 3.423613
TOP 2.756275
TRY 47.636612
TTD 7.958761
TWD 34.451933
TZS 3065.661464
UAH 49.037504
UGX 4210.402439
USD 1.176837
UYU 47.144706
UZS 14898.550633
VES 141.542248
VND 30766.650779
VUV 141.29205
WST 3.102248
XAF 656.025279
XAG 0.030177
XAU 0.000349
XCD 3.180462
XCG 2.11352
XDR 0.815885
XOF 656.025279
XPF 119.331742
YER 283.55937
ZAR 20.653556
ZMK 10592.964164
ZMW 27.238339
ZWL 378.94119
  • SCU

    0.0000

    12.72

    0%

  • CMSC

    -0.0400

    22.43

    -0.18%

  • JRI

    0.0000

    13.21

    0%

  • NGG

    -1.6300

    72.65

    -2.24%

  • CMSD

    -0.0300

    22.89

    -0.13%

  • RIO

    0.2900

    64.62

    +0.45%

  • SCS

    0.2100

    10.68

    +1.97%

  • BCC

    1.2000

    88.35

    +1.36%

  • BCE

    0.2200

    24.6

    +0.89%

  • RYCEF

    0.2000

    13.5

    +1.48%

  • GSK

    1.0100

    38.03

    +2.66%

  • BTI

    0.1500

    52.37

    +0.29%

  • VOD

    -0.0200

    11.3

    -0.18%

  • AZN

    2.5200

    73

    +3.45%

  • RBGPF

    0.9700

    68

    +1.43%

  • RELX

    0.4100

    53.09

    +0.77%

  • BP

    0.1900

    32.71

    +0.58%

Once-taboo ketamine booms for US at-home mental care
Once-taboo ketamine booms for US at-home mental care

Once-taboo ketamine booms for US at-home mental care

Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.

Text size:

A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.

Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.

"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."

Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.

It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.

In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.

- Ketamine 'babysitter' -

Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.

An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.

Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.

"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.

For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.

Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.

"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.

Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.

- 'Change your life' -

US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.

Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.

He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.

"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.

Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.

Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.

Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.

"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.

(B.Hartmann--BBZ)